Downregulation of stearoyl-CoA desaturase 1 (SCD-1) promotes resistance to imatinib in chronic Myeloid Leukemia

Basit Öğe Kaydı
dc.contributor.authorAltınok Güneş, Buket
dc.contributor.authorHekmatshoar, Yalda
dc.contributor.authorÖzkan, Tülin
dc.contributor.authorBozkurt, Süreyya
dc.contributor.authorErdoğan Aydos, O. Sena
dc.contributor.authorBüyükaşık, Yahya
dc.contributor.authorAladağ, Elifcan
dc.contributor.authorSunguroğlu, Asuman
dc.date.accessioned2023-01-26T08:08:50Z
dc.date.available2023-01-26T08:08:50Z
dc.date.issued2023en_US
dc.departmentFakülteler, Tıp Fakültesi, Temel Tıp Bilimleri, Tıbbi Biyoloji Ana Bilim Dalıen_US
dc.description.abstractChronic myeloid leukemia (CML) is a malignant hematopoietic stem cell disease resulting in the fusion of BCR and ABL genes and characterized by the presence of the reciprocal translocation t(9;22)(q34;q11). BCR-ABL, a product of the BCR-ABL fusion gene, is a structurally active tyrosine kinase and plays an important role in CML disease pathogenesis. Imatinib mesylate (IMA) is a strong and selective BCR-ABL tyrosine kinase inhibitor. Although IMA therapy is an effective treatment, patients may develop resistance to IMA therapy over time. This study investigated the possible genetic resistance mechanisms in patients developing resistance to IMA. We did DNA sequencing in order to detect BCR-ABL mutations, which are responsible for IMA resistance. Moreover, we analyzed the mRNA expression levels of genes responsible for apoptosis, such as BCL-2, P53, and other genes (SCD-1, PTEN). In a group of CML patients resistant to IMA, when compared with IMA-sensitive CML patients, a decrease in SCD-1 gene expression levels and an increase in BCL-2 gene expression levels was observed. In this case, the SCD-1 gene was thought to act as a tumor suppressor. The present study aimed to investigate the mechanisms involved in IMA resistance in CML patients and determine new targets that can be beneficial in choosing the effective treatment. Finally, the study suggests that the SCD-1 and BCL-2 genes may be mechanisms responsible for resistance.en_US
dc.identifier.citationAltınok Güneş, B., Hekmatshoar, Y., Özkan, T., Bozkurt, S., Erdoğan Aydos, O. S., Büyükaşık, Y., Aladağ, E., Sunguroğlu, A. (2023). Downregulation of stearoyl-CoA desaturase 1 (SCD-1) promotes resistance to imatinib in chronic Myeloid Leukemia. Mediterranean Journal of Hematology and Infectious Diseases, 15(1).en_US
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85151259021
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://hdl.handle.net/20.500.12939/3196
dc.identifier.volume15en_US
dc.identifier.wosWOS:000907654000001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorHekmatshoar, Yalda
dc.language.isoen
dc.relation.ispartofMediterranean Journal of Hematology and Infectious Diseases
dc.relation.isversionof10.4084/MJHID.2023.008en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBCR-ABL Mutationsen_US
dc.subjectCMLen_US
dc.subjectImatinib Resistanceen_US
dc.subjectSCD-1en_US
dc.titleDownregulation of stearoyl-CoA desaturase 1 (SCD-1) promotes resistance to imatinib in chronic Myeloid Leukemia
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Altinok+Gunes+PDF.pdf
Boyut:
877.52 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Temel Tıp Bilimleri Bölümü Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu